Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityNo recent work listed

Biao Li

Matched on ORCID iD 0000-0002-0493-2062; OpenAlex author ID A5100334863. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
15
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers

Papers 9

  1. Prediction of synchronous distant metastasis of primary pancreatic ductal adenocarcinoma using the radiomics features derived from 18F-FDG PET and MRI. Co-author DOI 10.1016/j.crad.2023.06.011↗
  2. Visualization research on ENT1/NIS dual-function gene therapy to reverse drug resistance mediated by MUC1 in GEM-resistant pancreatic cancer. Last author DOI 10.1016/j.nucmedbio.2023.108350↗
  3. The value of 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance whole-body scans and local enhancement scans in the preoperative staging an… Co-author DOI 10.21037/qims-22-731↗
  4. Prediction of synchronous distant metastasis of primary pancreatic ductal adenocarcinoma using the radiomics features derived from 18F-FDG PET/MR imaging Co-author DOI 10.21203/rs.3.rs-2040971/v1↗
  5. Joint Radiomics Analysis on 18F-FDG-PET-MRI of Primary Tumor to Predict the Risk of Synchronous Distant Metastasis in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-801341/v1↗
  6. Differentiating TP53 Mutation Status in Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI-Derived Radiomics. Co-author DOI 10.3389/fonc.2021.632130↗
  7. hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer. Last author DOI 10.1016/j.canlet.2020.03.015↗
  8. Performance of Multiparametric Functional Imaging and Texture Analysis in Predicting Synchronous Metastatic Disease in Pancreatic Ductal Adenocarcinoma Patient… Last author DOI 10.3389/fonc.2020.00198↗
  9. 18F-fluoro-2-deoxy-D-glucose retention index as a prognostic parameter in patients with pancreatic cancer. Last author DOI 10.1097/mnm.0000000000000178↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaozhu Lin · 6 shared papers, 2020–2023 · strength 0.91
  2. Jing Gao · 5 shared papers, 2020–2023 · strength 0.72
  3. Fei Miao · 4 shared papers, 2021–2023 · strength 0.60
  4. Kuangyu Shi · 3 shared papers, 2021–2023 · strength 0.46
  5. Min Zhang · 3 shared papers, 2014–2023 · strength 0.39
  6. Yun Xi · 3 shared papers, 2014–2023 · strength 0.39
  7. Weishen Wang · 1 shared paper, 2023 · strength 0.18
  8. Baiyong Shen · 1 shared paper, 2023 · strength 0.18
  9. Yongrui Bai · 1 shared paper, 2023 · strength 0.18
  10. Xiahan Chen · 1 shared paper, 2021 · strength 0.14
  11. Xiaohua Qian · 1 shared paper, 2021 · strength 0.14
  12. Peng Yuan · 1 shared paper, 2020 · strength 0.13
  13. Ting Li · 1 shared paper, 2020 · strength 0.13
  14. Mo‐Fang Liu · 1 shared paper, 2020 · strength 0.13
  15. Rui Guo · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.